Clinical trial
A Multicenter Randomized Phase III Study of Pemetrexed Versus Erlotinib in Patients With Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)
NCT00440414 is registered in ClinicalTrials.gov with Hellenic Oncology Research Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Randomized Phase III Study of Pemetrexed Versus Erlotinib in Patients With Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)
- Lead sponsor
- Hellenic Oncology Research Group
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2006
- Completion date
- April 30, 2010
- Enrollment
- 320 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
non small cell lung cancer